Morphoceuticals
Medford, US · Founded 2020 · Delaware corporation · 1 known investors
Find your way into Morphoceuticals
Morphoceuticals is a TechBio company mapping the "bioelectrome" — the body's cellular communication networks that govern tissue repair and organ regeneration. It combines multi-omics, bioelectric profiling, and AI to modulate ion channels for applications in regenerative medicine.
Founders & leadership
Board
AP
Alexander PickettBoard director
JB
Justin Briggsin𝕏Board MemberScientist, entrepreneur, and investor building companies at the nexus of biology, chemistry, and engineering
TH
Tamim Hamad J.J Al-ThaniBoard director
RH
Rosemarie HunzikerBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$13.3M disclosed across 2 rounds · 2023–2024
▶$3.5MraisedOct 2024 · 1 investors · BiotechnologyRule 506(b)
▶$3.5MraisedOct 2024 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael R. HuffordDirector
- Alexander PickettDirector
- Justin BriggsDirector
- Tamim Hamad J.J Al-ThaniDirector
- Rosemarie HunzikerDirector
- James JensonExecutive Officer, Director
- Offering amount
- $5.5M
- Amount sold
- $3.5M
- First sale
- Sep 2024
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$9.8MraisedJan 2023 · 3 investors · BiotechnologyRule 506(b)
▶$9.8MraisedJan 2023 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Alexander PickettDirector
- Michael LevinPromoter
- David GillExecutive Officer
- David KaplanPromoter
- Amy KruseDirector
- Michael R. HuffordExecutive Officer, Director
- Rosemarie HunzikerDirector
- Offering amount
- $9.8M
- Amount sold
- $9.8M
- Proceeds to insiders
- $612K
- First sale
- Jan 2023
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlap
nChroma Bio10 shared keywordsnChroma Bio develops in vivo targeted delivery and genetic engineering technologies for genetic medicine applications. The company works with academic founders and institutional investors focused on advancing gene therapy treatments.
Metaphorebio10 shared keywordsMetaphore develops a platform that measures biological activity inside cells at scale to design antibody medicines with novel mechanisms of action. The company aims to create antibodies that activate pathways, modulate signaling, and engage multiple targets to treat complex diseases.
Bioworld10 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies competing with Morphoceuticals for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Morphoceuticals do?
- Morphoceuticals is a TechBio company mapping the "bioelectrome" — the body's cellular communication networks that govern tissue repair and organ regeneration. It combines multi-omics, bioelectric profiling, and AI to modulate ion channels for applications in regenerative medicine.
- Who are Morphoceuticals's investors?
- Morphoceuticals's investors include Prime Movers Lab.
- How much funding has Morphoceuticals raised?
- Morphoceuticals has disclosed $13.3M raised across 2 rounds.
- Where is Morphoceuticals headquartered?
- Morphoceuticals is headquartered in Medford, US.